Ocular manifestations of mycoplasma-induced rash, mucositis
DIAGNOSIS AND TREATMENT The initial infectious workup was negative, which included blood culture, Group A Streptococcus rapid antigen screen, and nasopharyngeal swab polymerase chain reaction (PCR) testing for adenovirus, coronavirus, human metapneumovirus, rhinovirus, influenza A, influenza B, para...
Gespeichert in:
Veröffentlicht in: | Ophthalmology Times 2021-05, Vol.46 (8), p.30-31 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 31 |
---|---|
container_issue | 8 |
container_start_page | 30 |
container_title | Ophthalmology Times |
container_volume | 46 |
creator | Jin, Haoxing Douglas |
description | DIAGNOSIS AND TREATMENT The initial infectious workup was negative, which included blood culture, Group A Streptococcus rapid antigen screen, and nasopharyngeal swab polymerase chain reaction (PCR) testing for adenovirus, coronavirus, human metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Of the reported cases of MIRM in the literature, the mean age of presentation was 21.4 years (range 8-46), and all had conjunctival involvement without corneal involvement except for the 1 patient reported by Santos et al.5-10 Santos et al treated the patient with ocular occlusion, topic oxytetracycline ointment, and intravenous immunoglobulins at a dosage of 1 g/kg/d for 3 days with rapid improvement.8 None of the reported cases required amniotic membrane transplant and all recovered without ocular sequelae except for 1 with eyelid margin scar affecting the meibomian glands.9 CONCLUSION There have been no established treatment guidelines for ocular involvement of MIRM. Pediatricians and ophthalmologists should be familiar with this disease entity and consider amniotic membrane transplantation as an additional treatment option when the patient's clinical course worsens while on topical therapy. * In severe cases, amniotic membrane transplantation can afford patients symptomatic pain relief and aid in visual recovery. |
format | Article |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_reports_2533423774</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2533423774</sourcerecordid><originalsourceid>FETCH-proquest_reports_25334237743</originalsourceid><addsrcrecordid>eNqNzLEKwjAUQNEgCtbqPwRnA2leShFHUdxcHNzKI00x0jQ1Lxn8ex38AKe7HO6MFaqqpWgAYM4KWe1BSFD3JVsRPaWUGrQu2OFq8oCRexxdbylhcmEkHnru3yZMA5JH4cYuG9vxiPTYcZ9NIJccrdmix4Hs5teSbc-n2_Eiphhe-Ttro51CTNSqGkAraBoNf6EPxYw4Wg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2533423774</pqid></control><display><type>article</type><title>Ocular manifestations of mycoplasma-induced rash, mucositis</title><source>Alma/SFX Local Collection</source><creator>Jin, Haoxing Douglas</creator><creatorcontrib>Jin, Haoxing Douglas</creatorcontrib><description>DIAGNOSIS AND TREATMENT The initial infectious workup was negative, which included blood culture, Group A Streptococcus rapid antigen screen, and nasopharyngeal swab polymerase chain reaction (PCR) testing for adenovirus, coronavirus, human metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Of the reported cases of MIRM in the literature, the mean age of presentation was 21.4 years (range 8-46), and all had conjunctival involvement without corneal involvement except for the 1 patient reported by Santos et al.5-10 Santos et al treated the patient with ocular occlusion, topic oxytetracycline ointment, and intravenous immunoglobulins at a dosage of 1 g/kg/d for 3 days with rapid improvement.8 None of the reported cases required amniotic membrane transplant and all recovered without ocular sequelae except for 1 with eyelid margin scar affecting the meibomian glands.9 CONCLUSION There have been no established treatment guidelines for ocular involvement of MIRM. Pediatricians and ophthalmologists should be familiar with this disease entity and consider amniotic membrane transplantation as an additional treatment option when the patient's clinical course worsens while on topical therapy. * In severe cases, amniotic membrane transplantation can afford patients symptomatic pain relief and aid in visual recovery.</description><identifier>ISSN: 0193-032X</identifier><identifier>EISSN: 2150-7333</identifier><language>eng</language><publisher>Monmouth Junction: MultiMedia Healthcare Inc</publisher><subject>Antibiotics ; Cornea ; Fever ; Health sciences ; Hospitalization ; Influenza ; Mucositis ; Ophthalmology ; Pain ; Steroids ; Transplants & implants ; Visual acuity</subject><ispartof>Ophthalmology Times, 2021-05, Vol.46 (8), p.30-31</ispartof><rights>Copyright MultiMedia Healthcare Inc. May 2021</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,780,784,791</link.rule.ids></links><search><creatorcontrib>Jin, Haoxing Douglas</creatorcontrib><title>Ocular manifestations of mycoplasma-induced rash, mucositis</title><title>Ophthalmology Times</title><description>DIAGNOSIS AND TREATMENT The initial infectious workup was negative, which included blood culture, Group A Streptococcus rapid antigen screen, and nasopharyngeal swab polymerase chain reaction (PCR) testing for adenovirus, coronavirus, human metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Of the reported cases of MIRM in the literature, the mean age of presentation was 21.4 years (range 8-46), and all had conjunctival involvement without corneal involvement except for the 1 patient reported by Santos et al.5-10 Santos et al treated the patient with ocular occlusion, topic oxytetracycline ointment, and intravenous immunoglobulins at a dosage of 1 g/kg/d for 3 days with rapid improvement.8 None of the reported cases required amniotic membrane transplant and all recovered without ocular sequelae except for 1 with eyelid margin scar affecting the meibomian glands.9 CONCLUSION There have been no established treatment guidelines for ocular involvement of MIRM. Pediatricians and ophthalmologists should be familiar with this disease entity and consider amniotic membrane transplantation as an additional treatment option when the patient's clinical course worsens while on topical therapy. * In severe cases, amniotic membrane transplantation can afford patients symptomatic pain relief and aid in visual recovery.</description><subject>Antibiotics</subject><subject>Cornea</subject><subject>Fever</subject><subject>Health sciences</subject><subject>Hospitalization</subject><subject>Influenza</subject><subject>Mucositis</subject><subject>Ophthalmology</subject><subject>Pain</subject><subject>Steroids</subject><subject>Transplants & implants</subject><subject>Visual acuity</subject><issn>0193-032X</issn><issn>2150-7333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNzLEKwjAUQNEgCtbqPwRnA2leShFHUdxcHNzKI00x0jQ1Lxn8ex38AKe7HO6MFaqqpWgAYM4KWe1BSFD3JVsRPaWUGrQu2OFq8oCRexxdbylhcmEkHnru3yZMA5JH4cYuG9vxiPTYcZ9NIJccrdmix4Hs5teSbc-n2_Eiphhe-Ttro51CTNSqGkAraBoNf6EPxYw4Wg</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Jin, Haoxing Douglas</creator><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RQ</scope><scope>7WY</scope><scope>7X7</scope><scope>7XB</scope><scope>883</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K60</scope><scope>K6~</scope><scope>K9-</scope><scope>K9.</scope><scope>L.-</scope><scope>M0F</scope><scope>M0R</scope><scope>M0S</scope><scope>M2P</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>S0X</scope><scope>U9A</scope></search><sort><creationdate>20210501</creationdate><title>Ocular manifestations of mycoplasma-induced rash, mucositis</title><author>Jin, Haoxing Douglas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_reports_25334237743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibiotics</topic><topic>Cornea</topic><topic>Fever</topic><topic>Health sciences</topic><topic>Hospitalization</topic><topic>Influenza</topic><topic>Mucositis</topic><topic>Ophthalmology</topic><topic>Pain</topic><topic>Steroids</topic><topic>Transplants & implants</topic><topic>Visual acuity</topic><toplevel>online_resources</toplevel><creatorcontrib>Jin, Haoxing Douglas</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Career & Technical Education Database</collection><collection>Access via ABI/INFORM (ProQuest)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Trade & Industry (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Trade & Industry</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>Ophthalmology Times</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jin, Haoxing Douglas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ocular manifestations of mycoplasma-induced rash, mucositis</atitle><jtitle>Ophthalmology Times</jtitle><date>2021-05-01</date><risdate>2021</risdate><volume>46</volume><issue>8</issue><spage>30</spage><epage>31</epage><pages>30-31</pages><issn>0193-032X</issn><eissn>2150-7333</eissn><abstract>DIAGNOSIS AND TREATMENT The initial infectious workup was negative, which included blood culture, Group A Streptococcus rapid antigen screen, and nasopharyngeal swab polymerase chain reaction (PCR) testing for adenovirus, coronavirus, human metapneumovirus, rhinovirus, influenza A, influenza B, parainfluenza, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Of the reported cases of MIRM in the literature, the mean age of presentation was 21.4 years (range 8-46), and all had conjunctival involvement without corneal involvement except for the 1 patient reported by Santos et al.5-10 Santos et al treated the patient with ocular occlusion, topic oxytetracycline ointment, and intravenous immunoglobulins at a dosage of 1 g/kg/d for 3 days with rapid improvement.8 None of the reported cases required amniotic membrane transplant and all recovered without ocular sequelae except for 1 with eyelid margin scar affecting the meibomian glands.9 CONCLUSION There have been no established treatment guidelines for ocular involvement of MIRM. Pediatricians and ophthalmologists should be familiar with this disease entity and consider amniotic membrane transplantation as an additional treatment option when the patient's clinical course worsens while on topical therapy. * In severe cases, amniotic membrane transplantation can afford patients symptomatic pain relief and aid in visual recovery.</abstract><cop>Monmouth Junction</cop><pub>MultiMedia Healthcare Inc</pub></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0193-032X |
ispartof | Ophthalmology Times, 2021-05, Vol.46 (8), p.30-31 |
issn | 0193-032X 2150-7333 |
language | eng |
recordid | cdi_proquest_reports_2533423774 |
source | Alma/SFX Local Collection |
subjects | Antibiotics Cornea Fever Health sciences Hospitalization Influenza Mucositis Ophthalmology Pain Steroids Transplants & implants Visual acuity |
title | Ocular manifestations of mycoplasma-induced rash, mucositis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T05%3A21%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ocular%20manifestations%20of%20mycoplasma-induced%20rash,%20mucositis&rft.jtitle=Ophthalmology%20Times&rft.au=Jin,%20Haoxing%20Douglas&rft.date=2021-05-01&rft.volume=46&rft.issue=8&rft.spage=30&rft.epage=31&rft.pages=30-31&rft.issn=0193-032X&rft.eissn=2150-7333&rft_id=info:doi/&rft_dat=%3Cproquest%3E2533423774%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2533423774&rft_id=info:pmid/&rfr_iscdi=true |